Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2006

Shantha Biotechnics Consents to Manufacture Dengue Vaccine

  • Shantha Biotechnics will manufacture InViragen’s dengue vaccine candidate under an agreement between the two companies. This vaccine will be used to complete preclinical studies and initiate testing of its safety and efficacy in humans.

    The vaccine was designed by collaborators at the CDC to protect against all four of the dengue viruses. "InViragen and the CDC are using innovative recombinant technologies to create a novel vaccine," says Varaprasad Reddy, M.D., managing director of Shantha Biotechnics.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »